Incyte (INCY)
116.69
+0.90 (0.78%)
Upcoming Events
Latest Headlines
Incyte (INCY) PT Raised to $104 at Morgan Stanley
July 23, 2026 8:43 AM - StreetInsider
Incyte (INCY) PT Raised to $110 at JPMorgan
July 23, 2026 7:39 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
July 21, 2026 6:51 AM - StreetInsider
Form 4 INCYTE CORP For: Jul 16 Filed by: Tray Thomas
July 20, 2026 4:11 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Stein Steven H
July 20, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Mayes Patrick A
July 20, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: CAGNONI PABLO J
July 20, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Issa Mohamed Khairie
July 20, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Basi Ramitpal K
July 20, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Gardner David H
July 20, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Hoffman Richard A.
July 20, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Meury William
July 20, 2026 4:08 PM - SEC Filing
Halozyme and Incyte sign drug delivery licensing agreement
July 20, 2026 8:00 AM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
July 20, 2026 8:00 AM - PR NewsWire
Incyte to present six oncology studies at ESMO Congress 2026
July 17, 2026 1:11 PM - StreetInsider
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
July 17, 2026 1:10 PM - BizWire
Form 144 INCYTE CORP Filed by: Stein Steven H
July 16, 2026 4:16 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: CAGNONI PABLO J
July 16, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: Mayes Patrick A
July 16, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: Tray Thomas
July 16, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: Stein Steven H
July 16, 2026 4:07 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 15 Filed by: Issa Mohamed Khairie
July 16, 2026 4:07 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Issa Mohamed Khairie
July 16, 2026 4:05 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Stein Steven H
July 15, 2026 4:10 PM - SEC Filing
Incyte (INCY) Reiterated at Market Perform by Citizens on Updated VIVID-3 Data
July 15, 2026 4:37 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
July 14, 2026 6:57 AM - StreetInsider
Incyte (INCY) PT Raised to $134 at Barclays
July 14, 2026 5:12 AM - StreetInsider
Incyte (INCY) PT Raised to $112 at BMO Capital
July 13, 2026 7:33 AM - StreetInsider
Incyte reports 81% bleed reduction in VWD drug trial data
July 13, 2026 4:00 AM - StreetInsider
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
July 13, 2026 4:00 AM - BizWire
Incyte to Report Second Quarter Financial Results
July 8, 2026 8:00 AM - BizWire
Form 4 INCYTE CORP For: Jul 02 Filed by: Mayes Patrick A
July 7, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 02 Filed by: Tray Thomas
July 7, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 02 Filed by: Meury William
July 7, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 02 Filed by: Stein Steven H
July 7, 2026 4:09 PM - SEC Filing
Incyte (INCY) PT Raised to $99 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Form 8-K INCYTE CORP For: Jul 06
July 6, 2026 4:06 PM - SEC Filing
Incyte acquires Vega Therapeutics for $1.25B upfront
July 6, 2026 8:39 AM - StreetInsider
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
July 6, 2026 8:39 AM - BizWire
Form 4 INCYTE CORP For: Jun 30 Filed by: Baker Brothers Life Sciences LP
July 2, 2026 4:33 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 30 Filed by: Clancy Paul J
July 2, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 30 Filed by: HARRIGAN EDMUND
July 2, 2026 4:08 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
June 29, 2026 7:10 AM - StreetInsider
Star Therapeutics to present VGA039 trial data at ISTH 2026
June 26, 2026 9:00 AM - StreetInsider
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
June 26, 2026 9:00 AM - BizWire
Incyte's ruxolitinib cream gets positive EU review for eczema
June 26, 2026 7:30 AM - StreetInsider
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
June 26, 2026 7:30 AM - BizWire
Incyte (INCY) PT Raised to $113 at UBS
June 26, 2026 7:07 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
June 24, 2026 6:43 AM - StreetInsider
Incyte (INCY) PT Raised to $105 at Truist Securities
June 22, 2026 1:25 PM - StreetInsider
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
June 22, 2026 7:53 AM - StreetInsider
Form 8-K INCYTE CORP For: Jun 22
June 22, 2026 7:01 AM - SEC Filing
BMO Capital Upgrades Incyte (INCY) to Market Perform
June 22, 2026 4:19 AM - StreetInsider
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
June 19, 2026 2:01 AM - BizWire
BMO Capital on Incyte (INCY): ''989 Updates Provide More Context to ET/MF Opportunity'
June 15, 2026 10:10 AM - StreetInsider
Stifel Reiterates Buy Rating on Incyte (INCY)
June 15, 2026 9:24 AM - StreetInsider
Mirum and Incyte report positive phase 2 results for FOP treatment
June 14, 2026 4:35 PM - StreetInsider
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
June 14, 2026 4:35 PM - BizWire
NASDAQ: INCY shows 25% reduction in disease progression risk in lymphoma study
June 13, 2026 6:01 AM - StreetInsider
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
June 13, 2026 6:01 AM - BizWire
Form 4 INCYTE CORP For: Jun 08 Filed by: BAKER BROS. ADVISORS LP
June 10, 2026 4:41 PM - SEC Filing
Incyte (INCY) PT Raised to $136 at Guggenheim
June 10, 2026 4:39 PM - StreetInsider
Form 4 INCYTE CORP For: Jun 08 Filed by: HARRIGAN EDMUND
June 10, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: Clancy Paul J
June 10, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: FOUSE JACQUALYN A
June 10, 2026 4:07 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: BIENAIME JEAN JACQUES
June 10, 2026 4:06 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: High Katherine A
June 10, 2026 4:06 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: BRAWLEY OTIS W
June 10, 2026 4:06 PM - SEC Filing
Incyte (INCY) PT Raised to $140 at H.C. Wainwright
June 10, 2026 7:11 AM - StreetInsider
Form 8-K INCYTE CORP For: Jun 08
June 9, 2026 4:07 PM - SEC Filing
Stifel Reiterates Buy Rating on Incyte (INCY)
June 9, 2026 9:11 AM - StreetInsider
Form 4 INCYTE CORP For: Jun 04 Filed by: Tray Thomas
June 8, 2026 4:04 PM - SEC Filing
Incyte (INCY) PT Raised to $107 at Oppenheimer
June 8, 2026 2:49 PM - StreetInsider
Form 8-K INCYTE CORP For: Jun 08
June 8, 2026 7:06 AM - SEC Filing
Incyte to acquire Vega Therapeutics for $1.25 billion upfront
June 8, 2026 7:00 AM - StreetInsider
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
June 8, 2026 7:00 AM - BizWire
Form 144 INCYTE CORP Filed by: Tray Thomas
June 4, 2026 4:04 PM - SEC Filing
Mirum and Incyte to present zilurgisertib study results at ENDO 2026
June 4, 2026 8:06 AM - StreetInsider
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
June 4, 2026 8:05 AM - BizWire
Form 4 INCYTE CORP For: Jun 01 Filed by: CAGNONI PABLO J
June 3, 2026 4:58 PM - SEC Filing
Incyte (INCY) Reiterated at Market Perform by Citizens Amid Positive Trial Results
June 2, 2026 4:37 AM - StreetInsider
Incyte (INCY) Reiterated at Buy by Stifel
June 1, 2026 7:34 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
June 1, 2026 6:56 AM - StreetInsider
Incyte drug combination reduces lymphoma progression risk by 25%
June 1, 2026 2:53 AM - StreetInsider
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in P
May 30, 2026 8:00 AM - BizWire
Form 4 INCYTE CORP For: May 26 Filed by: Tray Thomas
May 28, 2026 4:47 PM - SEC Filing
Form 4 INCYTE CORP For: May 26 Filed by: BIENAIME JEAN JACQUES
May 28, 2026 4:46 PM - SEC Filing
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
May 28, 2026 4:07 PM - StreetInsider
Form DEFA14A INCYTE CORP
May 27, 2026 1:05 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Tray Thomas
May 26, 2026 4:11 PM - SEC Filing
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026 8:00 AM - BizWire
Bernstein SocGen Group Starts Incyte (INCY) at Market Perform
May 21, 2026 4:24 PM - StreetInsider
Form 4 INCYTE CORP For: May 19 Filed by: Clancy Paul J
May 21, 2026 4:02 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
May 21, 2026 6:38 AM - StreetInsider
Form 4/A INCYTE CORP For: May 06 Filed by: Stein Steven H
May 20, 2026 4:02 PM - SEC Filing
Form 4/A INCYTE CORP For: May 06 Filed by: CAGNONI PABLO J
May 20, 2026 4:02 PM - SEC Filing
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
May 20, 2026 8:00 AM - BizWire
JPMorgan Reinstates Incyte (INCY) at Neutral
May 20, 2026 4:30 AM - StreetInsider
Form 144 INCYTE CORP Filed by: Clancy Paul J
May 19, 2026 4:21 PM - SEC Filing
Incyte partners with Edison Scientific to deploy AI platform for drug research
May 19, 2026 8:00 AM - StreetInsider
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
May 19, 2026 8:00 AM - BizWire
Form SCHEDULE 13G/A INCYTE CORP Filed by: DODGE & COX
May 14, 2026 12:47 PM - SEC Filing
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
May 12, 2026 9:30 AM - BizWire
Form SCHEDULE 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP
May 11, 2026 5:00 PM - SEC Filing
Form 4 INCYTE CORP For: May 08 Filed by: Baker Brothers Life Sciences LP
May 11, 2026 4:46 PM - SEC Filing
Incyte reports 24-week data for Opzelura cream in moderate atopic dermatitis
May 7, 2026 8:50 AM - StreetInsider
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
May 7, 2026 8:50 AM - BizWire
Form 4 INCYTE CORP For: May 04 Filed by: Upadhyay Suketu
May 6, 2026 4:35 PM - SEC Filing
Form 3 INCYTE CORP For: May 04 Filed by: Upadhyay Suketu
May 6, 2026 4:34 PM - SEC Filing
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026 4:30 PM - BizWire
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
May 3, 2026 12:00 PM - PR NewsWire
FDA approves Incyte's once-daily Jakafi XR for blood disorders
May 1, 2026 5:28 PM - StreetInsider
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
May 1, 2026 5:28 PM - BizWire
Form SCHEDULE 13G INCYTE CORP Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 10:30 AM - SEC Filing
Incyte (INCY) PT Raised to $103 at UBS
April 30, 2026 8:59 AM - StreetInsider
Incyte (INCY) PT Raised to $123 at Stifel Following 'Solid' Q1 Results
April 29, 2026 9:23 AM - StreetInsider
Incyte to Present at Upcoming Investor Conferences
April 29, 2026 8:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
April 29, 2026 7:15 AM - StreetInsider
Incyte (INCY) PT Raised to $90 at Oppenheimer
April 28, 2026 4:32 PM - StreetInsider
Form ARS INCYTE CORP For: Dec 31
April 28, 2026 4:27 PM - SEC Filing
Form DEFA14A INCYTE CORP
April 28, 2026 4:27 PM - SEC Filing
Form DEF 14A INCYTE CORP For: Dec 31
April 28, 2026 4:27 PM - SEC Filing
Form 10-Q INCYTE CORP For: Mar 31
April 28, 2026 4:03 PM - SEC Filing
Incyte (INCY) PT Raised to $103 at Morgan Stanley
April 28, 2026 3:10 PM - StreetInsider
Incyte (INCY) PT Raised to $124 at TD Cowen
April 28, 2026 2:52 PM - StreetInsider
Incyte (INCY) Tops Q1 EPS by 46c; offers guidance
April 28, 2026 7:06 AM - StreetInsider
Form 8-K INCYTE CORP For: Apr 28
April 28, 2026 7:03 AM - SEC Filing
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
April 28, 2026 7:00 AM - BizWire
Incyte names Suketu Upadhyay as chief financial officer
April 28, 2026 7:00 AM - StreetInsider
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
April 28, 2026 7:00 AM - BizWire
Full Article List
